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1. Abbreviations
ATPS = ambient temperature, ambient pressure, saturated with
water vapour; ATS = American Thoracic Society; BTPS = body
temperature, ambient pressure, saturated with water vapour;
ECSC = European Community for Steel and Coal; ERS =
European Respiratory Society; FEV1 = forced expiratory
volume in 1 second; FVC = forced vital capacity; LLN = lower
limit of normal; PEF = peak expiratory flow; RSD = residual
standard deviation; SATS = South African Thoracic Society;
TLC = total lung capacity; VC = vital capacity.
2. Introduction
Spirometry is an essential part of a complete respiratory
evaluation, but inadequate standards and variations in
standard operating procedures exist that reduce its clinical
usefulness.1 Good quality spirometry necessitates a competent
operator, accurate and reliable equipment and a co-operative
patient.  Furthermore, it involves a series of standard
procedures and quality control checks to produce technically
satisfactory results.  Finally, the results take reference standards
into account and are interpreted with consideration of the
clinical indications for testing.
Various authorities have published comprehensive
guidelines for the standardisation of spirometry.2-4 More
recently, selective South African reference standards have
become available for the normal range of forced vital capacity
(FVC) and forced expiratory volume in 1 second (FEV1). 5-10 This
statement is prompted by increased utilisation of office
spirometry in South Africa and a perceived need for simplified
guidelines for use at primary contact level, i.e. in the clinic or
practice.  Diagnostic and research lung function laboratories
will require more comprehensive guidelines than proposed in
this document.
3. Definitions
Spirometry. Spirometry is one of a number of tests to evaluate
respiratory function.  The basic spirometric procedure involves
the measurement of gas volume and rate of airflow during a
maximal, forced expiration.  The mechanical properties of the
airways, lung, pleura, chest wall and respiratory muscles all
contribute to these results.
Spirometer. Spirometers operate on one of two principles:
• Volume-type spirometers determine volume directly and
have the advantages of low cost and ease of operation.
However, data processing and storage capacity may be
limited, unless the spirometer contains a microprocessor.
• Flow-type spirometers make use of a flow-sensor
(pneumotach) to derive volumes.  They are computerised,
provide quick reference values, produce flow-volume loops
enabling instant pattern recognition and can usually store
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large data sets.  On the other hand, they require greater
expertise to operate, calibrate and maintain.
Spirogram. Spirograms are the graphic displays produced by
spirometers.  In addition to graphs, they provide the measured
values (observed), the reference values (predicted) and the
measured values expressed as a percentage of the reference
values (% predicted).  Volume-type devices generate volume-
time curves (Fig. 1a) and flow-type devices generate flow-
volume curves (Fig. 1b).  Newer flow-type spirometers can
produce both types of curve.
Measurements.  Depending on type and level of
sophistication, spirometers can produce a range of measurements
that may assist in the clinical interpretation of results:
• Vital capacity (VC): VC is the total volume of gas inhaled from
the position of maximal expiration or exhaled from the
position of maximal inspiration.  It is measured with a
relaxed/slow breathing manoeuvre either during inspiration
or expiration.  VC is expressed in litres (BTPS).  BTPS refers to
a standardised volume at normal body temperature (37°C) at
ambient pressure, saturated with water vapour.
• Forced vital capacity (FVC): FVC is the maximum volume of
gas exhaled from the position of maximal inspiration by
means of a rapid, maximally forced expiratory effort,
expressed in litres (BTPS). 
• Forced expiratory volume in 1 second (FEV1): FEV1 is the volume
of gas exhaled during the first second of the FVC manoeuvre,
expressed in litres (BTPS).
• FEV1/FVC%: FEV1/FVC% is observed FEV1 expressed as per
cent of observed FVC (FEV1/FVC × 100).
• Peak expiratory flow (PEF): PEF is the maximum flow
generated with a FVC manoeuvre, expressed in litres per
second (BTPS).
Measurements of FVC, FEV1 and FEV1/FVC% are the
minimum required for diagnostic interpretation of results.  VC
measurements are useful for evaluating dynamic collapse of
small airways as found in emphysema.
Calibration.  Calibration is the process whereby the accuracy
(truthfulness) and precision (repeatability) of a device such as a
spirometer are tested and corrected using a gold standard such
as a calibration syringe with a standard volume.
Validation.  Validation is the process of establishing and
certifying the accuracy and precision of a device.
Operator. The term operator refers to the person performing
spirometry. 
4. Indications for spirometry
Specific and clear indications for spirometry are helpful in the
interpretation of results.  The most frequent clinical indications
for spirometry are listed below:
• To confirm a diagnosis in:
• Individuals with suspected obstructive or 
restrictive lung disease. 
• To grade respiratory impairment in.
• Medico-legal cases (e.g. assurance or disability)
• Individuals on treatment action plans (e.g. COPD)
• Individuals for lung resection, and individuals for 
thoracotomy or upper-abdominal surgery if they 
have chronic respiratory diseases. 
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Fig. 1.  (a) Volume-time, and (b) flow-volume curves.  In the flow-type
spirometer FEV1 is a derived value.  It can only be read from the flow-
volume graph if a 1-second timer is displayed.
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• To monitor changes in lung function in:
• Individuals with chronic respiratory diseases — to 
evaluate responses to treatment and disease 
progression.
• Workers regularly exposed to substances known to cause
respiratory diseases.11
• To screen for lung disease in:
• Smokers
• Individuals with persistent respiratory symptoms, 
including shortness of breath (dyspnoea), chest 
tightness, wheezing, coughing, sputum production and
chest pain.
• New employees with potential for exposure to 
substances known to cause respiratory diseases — 
to determine baseline lung function. 
• Workers with significant exposure to substances 
known to cause respiratory diseases.
Spirometry is frequently applied in the occupational
environment for surveillance purposes.  Its sensitivity and
specificity for detecting early disease varies and a screening
programme should be tapered to the specific needs of the
workplace.  For example, early changes of COPD or asbestosis
are detectable with spirometry, whereas early changes of
silicosis are better detected with chest radiography.  For
occupational asthma, because of its varying nature, a
respiratory symptoms questionnaire is frequently combined
with spirometry in screening or surveillance programmes.
5. Specifications for spirometers
5.1 Proof of validation
Spirometers may lack accuracy and precision.  Prospective
purchasers of equipment should seek its proof of validation.
Accuracy depends on the resolution (minimal detectable
volume or flow) and linearity (consistency) of the entire system
from the measuring components to the recording and display
components.  The American Thoracic Society (ATS) has
published minimal performance criteria for diagnostic and
monitoring spirometers and guidelines for validating
equipment using waveform-generated calibration syringes.2
Selective ATS recommendations for diagnostic spirometers are
provided in Tables I and II.  Table II provides standards for
graph output.  Manufacturers should follow these guidelines to
ensure that spirometers provide accurate data that are
comparable between different settings and over time.
Commercially available devices for monitoring of FEV1 and PEF
have disadvantages for office spirometry because they may be
less accurate, usually cannot be calibrated to ensure their
performance, and graphical displays may be absent or
inadequate for evaluation of test quality.  
Other recommendations include:
• The  BTPS-correction facility that meets ATS standards:  The
volume of exhaled gas is measured outside the body at
ambient conditions, designated ATPS (ambient temperature,
ambient pressure, saturated with water vapour).  These gas
measurements are corrected to reflect conditions inside the
lung (BTPS).  Without this facility, mathematical correction
of volumes has to be done manually.2
Table I.  Selective minimum volume and flow criteria for diagnostic spirometers 
Parameter Required range Accuracy (BTPS) Flow range (l/s) Time (s) Validation method 
VC 0.5 - 8 l ± 3% of reading or ± 0  - 14 30 3 l calibrated syringe
0.050 l, whichever 
is greater
FVC 0.5 - 8 l ± 3% of reading or ± 0  - 14 15 24 standard waveforms/
0.050 l, whichever 3 l calibrated syringe
is greater
FEV1 0.5 - 8 l ± 3% of reading or ± 0  - 14 1 24 standard waveforms
0.050 l, whichever 
is greater
PEF ± 10% of reading or 0  - 14 26 flow standard
± 0.400 l/s, whichever waveforms
is greater
Precision: ± 5% of
reading or ± 0.200 
l/s, whichever is greater
Table II.  Minimum scale factors for spirograms*
Parameter Required resolution Scaling
Volume 0.025 l 10 mm/l
Flow 0.1 l/s 5 mm/l/s
Time 0.2 s 2 cm/s
*For the flow-volume curve exhaled flow is plotted upwards and exhaled volume
towards the right in a 2:1 ratio.
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• Facility to generate real-time spirograms — to enhance
feedback and subject compliance.
• Stated source(s) of reference values and facility to select or
enter appropriate values manually.  
• Computer-driven technical quality indicators that meet ATS
standards (computer automatically evaluates test quality
based on pre-programmed criteria and gives prompts).  
• Printing facility for record-keeping purposes.
• Adequate facility to save large numbers of tests and test
quality indicators where needed, for example, for
occupational surveillance.
• Availability of after-sales service.
In addition to mechanical validation, spirometers can also
be tested in real-life situations involving human subjects.12
SATS recommend that independent professional advice
from a registered pulmonology training laboratory or the
Spirometry Training and Certification Committee of the South
African Thoracic Society (SATS) be obtained before a new
spirometer is acquired.
5.2 Calibration 
All diagnostic spirometers must be volume-calibrated at least
daily using a calibrated syringe with a volume of at least 3 l to
ensure that they remain accurate during use.  During industrial
surveys in which a large number of subject manoeuvres are
performed, calibration must be checked each morning and at
least twice during the day.  In circumstances where the
temperature may change markedly over the day, for example
in field surveys, more frequent temperature corrections are
necessary.  
Calibration involves the following steps:
1. The spirometer is switched to calibration mode (to
prevent BTPS-correction because room air is injected).  Room
temperature and barometric pressure readings are entered.  In
the absence of a barometer, barometric pressure readings can
be obtained from the local airport or weather bureau. 
2. Calibration syringe size is specified.  A 3 l syringe is
recommended.  Currently, the use of 2 l and 1 l syringes is not
validated.
3. The calibration syringe is connected to the spirometer and
the maximum volume of air injected.  Flow-type spirometers
are calibrated by injection of the maximum volume from the
syringe at least three times, each time at a different speed, to
cover a range of flow rates.  Calibration is complete when the
recorded volumes are within 3% or 50 ml, whichever is the
greater, for each flow rate tested.  In the event of in-line
(antimicrobial) filters being used, calibration should be done
with a filter installed.  The quality of the filter must be such
that the spirometry system still meets ATS standards.
4. Volume-type spirometers are checked for air leaks if the
measured volume remains outside the acceptable range.  A leak
can be detected by applying a slight constant positive pressure
with the calibration syringe while the spirometer outlet is
occluded.  Any volume change greater than 10 ml after 1 minute
indicates a leak.  Faults are corrected and calibration repeated.
5. Remaining problems are logged and referred to the
manufacturer without delay.  
The use of biological standards such as, for example, the
operator for daily volume calibration (biological calibration)
cannot replace the use of a calibration syringe.  Lung function
testing involves a ‘system’ consisting of three main
components: spirometer, operator and test subject.  Each of
these can be a source of variation in measurements and syringe
calibration is required in order to isolate the device. Biological
standards are useful for testing software irregularities such as,
for example, inconsistencies in the calculation of predicted
values.  Also, when they are used in conjunction with a
physical standard (calibration syringe), biological standards are
useful to test the proficiency of operators.
In addition to daily volume calibration, spirometers must be
maintained routinely according to the manufacturer’s
specifications.  This includes the cleaning of pneumotachs at
least once a week (more frequently if there is visible
condensation), as they are particularly sensitive to moisture
and secretions.  Other components of the spirometer, for
example the time clock, must also be calibrated from time to
time.  For these and other maintenance functions the
manufacturer must routinely check spirometers at least 6 - 12-
monthly. 
6. Responsibilities of operators
6.1  Skills
Operators must have an understanding of the principles
underlying the measurement and equipment operation.  They
must also be able to ensure optimal subject co-operation,
provide acceptable, reproducible results and recognise common
abnormalities. Training of pulmonary medical technologists
includes this competency and competency to perform
advanced lung function tests and laboratory quality assurance.
The SATS is in the process of developing a curriculum, training
materials and a means of certification of proficiency in
performing spirometry for people other than pulmonary
medical technologists.   
6.2  Quality assurance
A quality assurance programme is critical to ensure a well-
functioning spirometry laboratory.13 This may be difficult to
attain in a routine clinical practice.  At a minimum, a
calibration and maintenance log as well as electronic or hard
copies of whole spirograms must be kept so that accuracy and
precision of past tests can be verified.  Additionally, standard
operating procedures should be documented and kept for
reference purposes.
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6.3 Infection control
Various components of the spirometry system, including
mouthpieces, nose clips, pneumotachs, valves and tubing, are
potential vehicles for transmission of infection to subjects and
staff.  Transmission of upper respiratory tract infections, enteric
infections and blood-borne infections such as hepatitis and
HIV, can potentially occur through direct contact when test
subjects have open sores in the mouth, bleeding gums or
haemoptysis.  Tuberculosis and viral and nosocomial infections
can also occur, indirectly, through inhalation of aerosol droplets
from the spirometer or surroundings.  The type of test
manoeuvre determines whether inhalation from the spirometer
takes place.  This has a major influence on the extent of
infection control needed.  An expiratory manoeuvre without
inhalation from the spirometer reduces the potential for cross-
infection dramatically and is the method of choice for mass
screening purposes.  
Infection control recommendations for expiratory
manoeuvres without inhalation from the spirometer:
• Spirometry should be performed in a well-lit and ventilated
area.
• Hands must be washed immediately after direct handling of
mouthpieces or other potentially contaminated spirometer
parts, and between subjects, to avoid operator exposure and
cross-contamination.  Gloves should be worn for personal
protection if there are open cuts or sores on the operator’s
hands.
• A clean disposable mouthpiece or a disinfected re-usable
mouthpiece must be used for every test subject.  Any other
spirometer part coming into direct contact with mucosal
surfaces must be decontaminated/sterilised.
• Spirometers must be cleaned regularly according to the
manufacturer’s recommendations and the frequency of tests
done.  Any part with visible condensation from expired air
must also be decontaminated before re-use.
Additional infection control recommendations for
manoeuvres involving inhalation from the spirometer system
or part of the system:
• In-line filters must be used and replaced after each subject,
or
• Involved parts of the system (i.e. spirometer, breathing
tubes and resistive element of the pneumotach) must be
decontaminated/sterilised/flushed after each subject.
(Note: re-calibration is necessary every time a system has
been dismantled for decontamination.) 
Special precautions for patients with haemoptysis or
known transmissible infections such as tuberculosis:
• In-line filters must be used routinely (even if expiratory
manoeuvres are performed exclusively) with sterilisation of
contaminated surfaces only, or 
• Equipment must be decontaminated/sterilised/flushed
completely after each case.  Testing such cases at the end of
the day will allow for overnight decontamination of
equipment.  (Note: indications for spirometry in known
active tuberculosis are limited.)
For decontamination/sterilisation procedures, consult the
user manual or contact the infection control unit or lung
function laboratory at an academic hospital near you.
7. Preparation of subjects
7.1 Exclusion criteria
The main exclusion criterion for spirometry in routine clinical
practice is current respiratory infections in individuals for
impairment/disability assessment.  Respiratory infections can
cause temporary lung function impairment and spirometry, if
required, should be done only once infections, including
tuberculosis, have resolved.  
7.2 Personal information
The following information is required for reference purposes
(section 9.2) and must be entered into the programme: weight
and standing height, age, sex and race.  For height and weight
measurements the subject should be barefoot and wear only
light clothing.  It is also useful for interpretation purposes to
record the time of last bronchodilator use and smoking status.
7.3 Positioning and preparation
The subject must be made to feel comfortable.  Shelter him/her
from other subjects to minimise inhibitions or distractions.
Loosen tight clothing.  Leave well-fitting dentures in, but
remove loose-fitting ones.  Test the subject sitting upright on a
firm chair with his/her chin slightly elevated and neck slightly
extended.  This posture should be maintained during the
forced expiration.  Discourage excessive bending at the waist.
Use of a nose clip is strongly recommended.  Instruct the
patient when to insert the mouthpiece, for example, at the end
of maximal inspiration.  Ensure that the subject does not bite
the mouthpiece too hard, that the lips are sealed tightly around
it, and that the tongue does not obstruct the mouthpiece in any
way.
Ensure maximum subject co-operation.  Submaximal efforts
are a frequent cause of abnormal results.  Explain techniques in
simple terms and demonstrate them to the patient.  For
example, explain that: ‘I am going to have you blow into the
machine to see how big your lungs are and how fast the air
comes out.  It does not hurt but requires your co-operation and
lots of effort.’  Explain and demonstrate the use of a nose clip
and mouthpiece.  Remind the patient of a few key points.  ‘Be
sure to take as deep a breath as possible, blast out hard and do
not stop blowing until I tell you to do so.’  Give feedback about
the performance, encourage and describe what improvements
can be made.
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8. Execution of tests
8.1 Test manoeuvres
Test manoeuvres are determined in part by the setting and
level of sophistication of the spirometer:
• Expiratory-only method. For reasons of ease, cost and
infection control this method is recommended for mass
screening.  It consists of a FVC test with or without a slow
VC test.  For the FVC test, the test subject is required to
inhale maximally before inserting the mouthpiece and
starting the test.  Expiration must be rapid, forceful and
complete, lasting at least 6 seconds.  If significant
obstruction is demonstrated, proceed with a slow VC test.
The slow VC test is preceded by a maximal inspiration, the
mouthpiece is inserted and the patient then breathes out in
a relaxed fashion and for as long as possible.  Allow for up
to 15 seconds.  Only the VC is recorded.  The rationale for
performing a slow VC test is as follows: the slow VC provides
additional information on the characteristics of the obstructive
defect.  A reduction in FVC compared with slow VC suggests
dynamic collapse of unsupported airways during forced expiration
leading to air trapping.  This pattern is typically seen in
emphysema.
• Inspiratory-expiratory method. With this method both
inspiration and expiration are recorded to generate a flow-
volume curve on a flow-type spirometer.  Typically, after
insertion of the mouthpiece, a period of quiet breathing is
followed by a complete expiration, a rapid, forceful and
complete inspiration and finally, a rapid, forceful and
complete expiration.  Some programmes prompt for an
expiratory manoeuvre followed by an inspiratory
manoeuvre.  However, the first method is recommended,
because this will reveal air trapping as described in the
previous section.  Reduced FVC compared with forced,
inspiratory VC is suggestive of air trapping.
8.2 Test quality
The final step in ensuring data quality is the evaluation of
spirograms for acceptability and reproducibility.
8.2.1 Acceptability 
A technically acceptable FVC trial (Fig. 1) must exhibit the
following qualities:
• A ‘crisp’, unhesitating start.
• PEF of the flow-volume curve achieved within the first 25%
of the volume expired from maximum inspiration.  (Most
individuals are able to produce PEF within the first 15% of
the volume expired.)
• A continuous smooth exhalation without artefacts caused
by coughing, variable effort, second inhalations or leaks
influencing FEV1 or FVC.
• A complete exhalation (to the point where no more air can
be expelled from the lungs), lasting until the volume-time
curve has clearly reached a plateau or the flow-volume
curve has progressively returned to zero flow.  
All technically unsatisfactory trials must be rejected.
Common patterns are illustrated in Figs. 2 - 4.  
8.2.2 Reproducibility 
Suboptimal effort by the test subject is a frequent cause of
diminished lung function results.  Ensuring reproducibility of
test results is a way of verifying that the test subject co-
operates fully and provides  maximal effort.  Reproducibility is
defined as two curves in which the difference in FVC and
FEV1, respectively, do not exceed 0.2 l.  Reproducibility is
usually evident from the spirogram at a glance (Fig. 5).  Testing
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Fig. 2.  (a) Volume-time, and (b) flow-volume curves exhibiting
cough artefacts (X) that can influence observed FVC and FEV1.
Volume-time graphs are better for evaluating end-of-test quality. 
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must continue until a minimum of three technically acceptable
FVC trials have been obtained, at least two of which are
reproducible.  However, no more than eight trials should be
performed during a single session, because fatigue induced by
repeated FVC trials can lead to reduced results.  Subjects with
asthma sometimes demonstrate spirometry-induced
bronchoconstriction leading to a progressive reduction in lung
function with successive trials.  This finding will be of interest
to the clinician and all acceptable curves should be kept for
reporting.  Failure to obtain reproducibility after eight trials
must be documented, but selection of the best curve may
proceed.  
9. Interpretation of results
9.1 Selection of the best test
For diagnostic purposes, the best spirogram must be inspected,
i. e. the graph with the largest sum of FVC and FEV1.  For
impairment or severity grading the highest values recorded for
FVC and FEV1 must be selected from all acceptable curves,
including the post bronchodilator curves, even if they come
from separate curves.  
9.2 Reference standards
An individual’s observed results are evaluated for
abnormalities against predicted results derived from a normal
Fig. 3.  (a) Volume-time, and (b) flow-volume curves exhibiting
glottis closure (X) resulting in premature termination of effort and
reduced observed FVC.
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Fig. 4.  (a) Volume-time curve exhibiting a slow rise and the end-of-
test not reaching a plateau, and (b) flow-volume curve with a late
peak flow and an abrupt end-of-test.  Failure to demonstrate
reproducibility will confirm these as submaximal efforts.
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reference population.  The comparison is made as per cent
observed/predicted.  Predicted values for FVC and FEV1 are
calculated from equations based on age, height and gender
because these characteristics are the most important
determinants of lung and airway size in healthy individuals.14-17
Office spirometers are typically programmed with prediction
equations derived from the study of Caucasians, such as the
European Community for Steel and Coal (ECSC) (Table III).17
Caucasians, when compared with indigenous populations,
usually show higher FVC and FEV1, but similar or lower
FEV1/FVC%.  The use of inappropriate predicted values can
result in an increased rate of abnormal results in clinically
normal people.
The use of prediction equations based on studies carried out
in South Africa, has been investigated.18 Indigenous equations,
as detailed in Table IV, are, where available, recommended for
population screening, surveillance and medico-legal purposes.
However, it is acknowledged that the application of these
predicted values in every context where spirometry is used
may present practical difficulties.  Alternatively, office
spirometers usually have a facility for application of a
correction factor such as 0.9 for adjusting predicted values for
Caucasians with a view to their being used for indigenous
populations.  Adjusted per cent predicted can be calculated
using the formula: 
[Observed indigenous /(predicted Caucasian × 0.9)] × 100]
While the use of such correction factors is acceptable, when
understood as an approximation, use of the recommended
prediction equations is the preferred option.  Operators must
familiarise themselves with their spirometers regarding these
conditions.              
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Table III.  ECSC prediction equations* from Quanjer et al.17
Parameter Prediction equation 1.64 × RSD
Men
FEV1
† (l) 4.30H – 0.029A – 2.49 0.84
FVC† (l) 5.76H – 0.026A – 4.34 1.00
FEV1/VC% – 0.18A + 87.21 11.8
Women
FEV1
† (l) 3.95H – 0.025A – 2.60 0.62
FVC† (l) 4.43H – 0.026A – 2.89 0.71
FEV1/FVC% – 0.19A + 89.10 10.7
*Valid for age 18 - 70 years. Between age 18 and 25 years substitute age 25 in the
equation.  The lower limit of normal (LLN) is the lower 5th percentile: predicted
value – 1.64 × RSD.
†80% predicted is an accepted alternative LLN.
H = standing height (m); A = age (years); RSD = residual standard deviation.
Table IV.  Prediction equations* from Louw et al.5 (African men)
and Mokoetle et al.8 (African women)
Parameter Prediction equation 1.64 × RSD
Men
FEV1 (l) 2.9H – 0.027A – 0.54 0.75
FVC (l) 4.8H – 0.024A – 3.08 0.89
Women
FEV1 (l) 3.4H – 0.028A – 1.87 0.64
FVC (l) 4.5H – 0.023A – 3.04 0.67
*The lower limit of normal (LLN) is the lower 5th percentile: predicted value – 1.64 ×
RSD. 80% is an acceptable alternative LLN.
H= standing height (m); A = age (years); RSD = residual standard deviation.  
Fig. 5. (a) Volume-time, and (b) flow-volume curves each
demonstrating three acceptable FVC trials, only #2 and #3 of which
are reproducible.
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9.3 Diagnosis and severity grade
9.3.1 Algorithm
The major aims of interpreting spirometric results are to
confirm the clinical diagnosis and to estimate the severity of
the disease.  An algorithm is presented (Fig. 6) for categorising
spirometric results as obstructive, normal or restrictive
patterns.  The algorithm employs three variables, namely
FEV1/FVC%, % predicted FVC and % predicted FEV1.  The
interpretative strategy proposed is based on published
guidelines,19 but the lower limit of normal (LLN) for
FEV1/FVC% has been adapted to conform to current diagnostic
guidelines for chronic obstructive pulmonary disease (COPD).20
The LLN for FEV1/FVC%, FVC and FEV1, is the 5th
percentile (see Tables III and IV). Eighty per cent predicted is
an acceptable alternative LLN for FVC and FEV1. The use of a
fixed percentage for the LLN for FEV1/FVC% (usually 70% or
75%) is a pragmatic clinical approach, but has limitations. For
screening purposes it may be more accurate to use the 5th
percentile to minimise misclassifications of borderline values. A
reduced FEV1 should always be regarded as abnormal. When
this is the only finding on the spirogram, further investigations,
including a bronchodilator test, may be necessary to define the
abnormality (see Fig. 6).
Non-clinicians such as, for example, occupational health
nurses can use the algorithm to identify cases for referral.  The
experienced clinician will use this information in combination
with pre-test information, including the indications for testing,
and his/her knowledge about the case to make a final clinical
diagnosis.
Fig. 6.  An algorithm for categorising spirometric results is
presented.  The observed FEV1/FVC is expressed as a percentage and
the lower limit of normal (LLN) is defined as 70%.  FVC and FEV1
are based on per cent predicted (%pred) and LLN defined as 80%
(BD = bronchodilator).
Is the test acceptable? Yes
Is the test reproductible? Yes
Are the reference values appropriate? Yes
FEV1/FVC% < 70%:
OBSTRUCTIVE
(% pred FVC < 80%:
OBSTRUCTIVE with reduced VC)
FEV1/FVC% =  or > 70%:
NON-OBSTRUCTIVE
Perform BD-test %pred FVC < 80%
RESTRICTIVE
%pred FVC =  or > 80%:
NORMAL
(Except when %pred FEV1 < 80%:
further tests indicated, including BD test)
Grade impairment Grade impairment
Fig. 7.  Flow-volume curves exhibiting typical (a) reversible
obstruction in an asthmatic, and (b) non-reversible obstruction in a
person with COPD (black = pre-bronchodilator, grey = post-
bronchodilator, broken line = reference standard).
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9.3.2 Obstructive defect
An obstructive ventilatory defect is defined as a
disproportionate reduction in maximal airflow from the lung
with respect to the maximal volume that can be displaced from
the lung.  The experienced clinician will readily recognise a
pattern of expiratory airflow limitation on the flow-volume
curve (Fig. 7).  The diagnosis of an obstructive defect should be
followed up with a bronchodilator test to examine the nature of
the obstruction.  Severity of obstruction is graded according to
the worst affected spirometric parameter, usually % predicted
FEV1.  Mild obstructive defects could be missed if there is
under-estimation of FVC due to unacceptable end-of-test
criteria.
9.3.3 Restrictive defect
A restrictive ventilatory defect is characterised physiologically
by a reduction in total lung capacity (TLC) as determined by
advanced lung function testing.  One may infer a restrictive
defect when FEV1/FVC% is normal or high (non-obstructive)
and FVC is reduced (Fig. 8).  The severity of the restrictive
defect is graded according to TLC when available, otherwise it
is graded according to the worst affected spirometric
parameter, and usually % predicted FVC.
A range of conditions can reduce FVC per se:
• Conditions impeding movement of the chest wall (e.g. pain,
pleural thickening or effusion, neuromuscular weakness,
skeletal abnormality or hyperinflation with air trapping as
found in COPD).
• Diffuse conditions of lung parenchyma causing stiffness of
the lung (e.g. interstitial lung disease with fibrosis,
pulmonary oedema).
• Conditions causing reduced communicating lung volume
(e.g. lung resection, occlusion of a main bronchus, post-
tuberculous lung destruction and space-occupying lesions
in the chest). 
Restrictive abnormalities are often over-diagnosed because
of poor effort by the patient (Figs 3 and 4) or the use of
inappropriate prediction equations.  Nevertheless, diagnostic
interpretation of a reduced FVC can be difficult and referral to
a specialist must be considered after exclusion of obvious
technical causes.
9.3.4 Obstruction with reduced FVC
This pattern consists of reduced FEV1/FVC% and FVC and is
usually found in obstructive conditions such as, for example,
severe emphysema or asthma, but a combination of an
obstructive and restrictive condition can produce a similar
result.  Other VC manoeuvres (section 8.1) and a
bronchodilator test (Fig. 7), performed in the office, can assist
in further defining the underlying disease.  The severity of the
defect is graded according to the indicator showing the most
severe defect, usually % predicted FEV1.
9.3.5 Bronchodilator response
The purpose of a bronchodilator test is to determine whether
airway obstruction, as measured by spirometry, is reversible
with inhaled beta-2 agonists (Fig. 7).  A bronchodilator test can
be standardised as follows:
1. Two reproducible FVC trials are obtained from the test
subject.
2. Two puffs (400 µg) of salbutamol or equivalent are
administered.
3. A waiting period of at least 10 minutes is introduced.
4. Two reproducible FVC trials are again obtained.
5. The best post-bronchodilator FEV1 is evaluated for a
significant improvement of at least 200 ml and 12% from the
best pre-bronchodilator FEV1.  Per cent improvement in FEV1
can be calculated using the formula: 
[FEV1 pre-BD - FEV1 post-BD/ FEV1 pre-BD] × 100
The post-bronchodilator FVC trials must be done at least 10
minutes after administration of the bronchodilator, but ideally
only after 20 - 30 minutes, as this is the time of maximum effect
of most short-acting bronchodilators.  Both the pre- and post-
bronchodilator FEV1 must be reproducible; otherwise a
response cannot be confidently interpreted as such.  For an
accurate interpretation of a negative response, subjects must
have been weaned from short-acting bronchodilators for at
least 4 hours and long-acting bronchodilators and theophylline
for at least 12 hours, if medically possible.  A number of
factors, including the dose of bronchodilator, recent prior
bronchodilator medication and timing of the post-
bronchodilator FVC trials can influence the magnitude of the
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Fig. 8.  Flow-volume curve exhibiting a typical restrictive pattern in
a person with sarcoidosis (broken line = reference curve).  The
‘shoulder’ on the down-slope of the expiratory curve was reproducible
(not demonstrated).  It represents a normal physiological
phenomenon of the expiratory curve.
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response significantly.  Each practice should decide on a
standard protocol.
9.3.6 Grading respiratory disease severity 
The main indications for grading respiratory disease severity
are to quantify respiratory impairment/disability for medico-
legal purposes, and to optimise and standardise treatment
practices.
Guidelines for grading spirometric impairment correlate
different lung function tests, including spirometry, with the
ability to perform physical activities.21 For this purpose criteria
for spirometry, performed in the office, are included (Table V)
for use in conjunction with the algorithm. LLN for FEV1/FVC%
has been adapted to conform to current diagnostic guidelines
for chronic obstructive pulmonary disease (COPD).20 A
severity grade is awarded according to the worst affected
parameter. The grading of obstruction should be based on the
post-bronchodilator values.
In most cases simple spirometry will be sufficient for
evaluating respiratory impairment.  However, if discordance is
found between spirometry and the stated level of dyspnoea or
clinical evaluation, additional lung function tests may be
indicated and the subject must be referred to a specialist with
diagnostic lung function facilities.  Further tests might include
carbon monoxide diffusing capacity (DLCO) and/or exercise
testing.  In addition to spirometry, DLCO is clinically one of the
most useful tests of lung function.  It is especially useful in
interstitial lung diseases, including the pneumoconioses, where
gas transfer at alveolar level might be affected
disproportionately to the mechanical properties of the lung.
Another factor that needs to be considered during the clinical
evaluation is the potential contribution of extra-pulmonary
disease, for example, ischaemic heart disease, to total
impairment.  Also, because of its varying nature, the usual
spirometric criteria do not apply to asthma as far as assessment
of impairment/disability is concerned.22
As stated before, treatment guidelines also use spirometric
grading to standardise treatment practices.  These guidelines
for grading severity are usually disease-specific and their main
aims are to control the disease and improve prognosis.
Therefore, the spirometric grading could differ from general
guidelines aimed primarily at quantifying functional
impairment.
9.4 Reporting
Spirometry reports must contain the following information:
• Identification of subject and date of testing.
• Personal  information (see section 7.2) and origin of
reference values.
• Numerical values and graphs to assess acceptability and
reproducibility (at least two curves, but preferably three).
• Latest calibration date.
The report should refer to lung function and not disease
(e.g. ‘obstructive lung function defect without reversibility’
rather than ‘chronic obstructive lung disease’), unless the
reporter is a clinician and has full clinical details to make an
appropriate diagnosis. 
10. Spirometry Training and
Certification Committee
For further information on training opportunities, readers may
contact the Chair, Spirometry and Training Certification
Committee, South African Thoracic Society, PO Box 16433,
Vlaeberg, 8018.
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